Upcoming events

Watchman™ Ewolution prospective registry - 3 months results & clinical impact

Sponsored by Boston Scientific

Summary: Interview with Prof. Martin W. Bergmann on the EWOLUTION registry the largest prospective real-life LAAC registry with over 1,000 patients studied. The EWOLUTION registry is a multicenter study designed to obtain clinical data on procedural success, complication rates, incidence of stroke, bleeding and long-term patient outcomes.

 

EWOLUTION Key Results & Findings1

 

HIGH RISK POPULATION

72%

Patients not eligible for OAC

3 MONTHS RESULTS

99%

No or minimal leak at first follow-up

 

  • Device or procedure related serious adverse events (SAE) rates at 92 days were similar if patients were treated with warfarin or DAPT (2.6% vs. 4.8%, respectively).
  • Bleeding SAE rates were also similar if warfarin or DAPT was used post-implantation (4.8% vs. 3.6%, respectively).
  • Registry on WATCHMAN™ Outcomes in Real-Life Utilization

 
Reference:

1Bergmann M. W. et al. presented at EuroPCR 2016, Paris May 17th-20th

 

Boston Scientific Disclaimer

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. SH-402401-AA - JUNE 2016

Sponsor

With an unrestricted educational grant from Boston Scientific

Authors

Prof. Martin W. Bergmann

Disclaimer

This case report does not reflect the opinion of PCR or PCRonline, nor does it engage their responsibility.